| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
4,813 |
4,273 |
$1.14M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
6,201 |
5,054 |
$1.14M |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
3,429 |
2,579 |
$581K |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
2,786 |
2,267 |
$579K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
1,212 |
778 |
$303K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
346 |
258 |
$149K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
457 |
402 |
$143K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
558 |
505 |
$125K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
1,703 |
1,536 |
$75K |
| 80053 |
Comprehensive metabolic panel |
7,629 |
6,375 |
$74K |
| 70450 |
Computed tomography, head or brain; without contrast material |
283 |
237 |
$64K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
363 |
296 |
$48K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
300 |
257 |
$44K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
809 |
705 |
$39K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
7,138 |
5,708 |
$37K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
1,203 |
967 |
$32K |
| 80061 |
Lipid panel |
2,262 |
2,139 |
$25K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
719 |
653 |
$22K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
285 |
209 |
$18K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
523 |
477 |
$15K |
| 81001 |
|
3,386 |
2,921 |
$11K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
811 |
699 |
$11K |
| 84443 |
Thyroid stimulating hormone (TSH) |
703 |
650 |
$9K |
| 71046 |
Radiologic examination, chest; 2 views |
935 |
837 |
$9K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
2,260 |
1,866 |
$8K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
894 |
833 |
$8K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
373 |
351 |
$8K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
171 |
149 |
$8K |
| 84484 |
|
967 |
734 |
$7K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
854 |
743 |
$6K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
19 |
18 |
$6K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
554 |
439 |
$5K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
202 |
195 |
$4K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
913 |
726 |
$4K |
| 83690 |
|
712 |
604 |
$4K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
177 |
168 |
$3K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
13 |
12 |
$3K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
1,889 |
1,516 |
$3K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
31 |
28 |
$2K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
15 |
15 |
$2K |
| 81025 |
|
332 |
304 |
$2K |
| 87081 |
|
212 |
205 |
$2K |
| 36415 |
Collection of venous blood by venipuncture |
5,928 |
5,025 |
$2K |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
42 |
41 |
$2K |
| 80050 |
General health panel |
195 |
179 |
$1K |
| 85027 |
|
251 |
238 |
$1K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
172 |
137 |
$1K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
1,790 |
1,414 |
$1K |
| 84439 |
|
122 |
118 |
$1K |
| 82607 |
|
74 |
71 |
$905.03 |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
12 |
12 |
$791.92 |
| 87186 |
|
107 |
98 |
$622.32 |
| 94726 |
|
14 |
12 |
$540.27 |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
15 |
15 |
$435.12 |
| 94729 |
|
14 |
12 |
$413.45 |
| 82043 |
|
78 |
73 |
$365.93 |
| 86140 |
|
87 |
69 |
$353.10 |
| 82570 |
|
82 |
77 |
$349.89 |
| 0240U |
|
12 |
12 |
$323.19 |
| 81015 |
|
80 |
74 |
$203.15 |
| G0103 |
Prostate cancer screening; prostate specific antigen test (psa) |
13 |
13 |
$193.80 |
| J2704 |
Injection, propofol, 10 mg |
910 |
820 |
$121.57 |
| 83735 |
|
25 |
25 |
$120.71 |
| 85610 |
|
68 |
49 |
$112.27 |
| 83880 |
|
14 |
13 |
$90.13 |
| 82553 |
|
15 |
12 |
$66.15 |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
12 |
12 |
$50.05 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
1,091 |
971 |
$38.67 |
| 36416 |
|
18 |
15 |
$35.00 |
| 82962 |
|
14 |
12 |
$33.00 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
1,739 |
1,451 |
$4.87 |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
370 |
326 |
$2.55 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
2,105 |
1,714 |
$2.01 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
336 |
302 |
$0.78 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
329 |
281 |
$0.54 |
| G1004 |
Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program |
1,873 |
1,601 |
$0.01 |
| A9270 |
Non-covered item or service |
2,003 |
1,444 |
$0.00 |
| J7050 |
Infusion, normal saline solution, 250 cc |
191 |
83 |
$0.00 |
| J1170 |
Injection, hydromorphone, up to 4 mg |
80 |
69 |
$0.00 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
27 |
26 |
$0.00 |
| J3490 |
Unclassified drugs |
42 |
27 |
$0.00 |
| 71045 |
Radiologic examination, chest; single view |
28 |
26 |
$0.00 |
| G1010 |
Clinical decision support mechanism stanson, as defined by the medicare appropriate use criteria program |
266 |
232 |
$0.00 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
13 |
13 |
$0.00 |
| Q9966 |
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml |
12 |
12 |
$0.00 |